



---

Year: 2020

---

## Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study

Pigorsch, Steffi U ; Kampf, Severin ; Oechsner, Markus ; Mayinger, Michael C ; Mozes, Petra ;  
Devecka, Michal ; Kessel, Kerstin K ; Combs, Stephanie E ; Wilkens, Jan J

**Abstract:** Background: The ESCALOX trial was designed as a multicenter, randomized prospective dose escalation study for head and neck cancer. Therefore, feasibility of treatment planning via different treatment planning systems (TPS) and radiotherapy (RT) techniques is essential. We hypothesized the comparability of dose distributions for simultaneous integrated boost (SIB) volumes respecting the constraints by different TPS and RT techniques. Methods: CT data sets of the first six patients (all male, mean age: 61.3 years) of the pre-study (up to 77 Gy) were used for comparison of IMRT, VMAT, and helical tomotherapy (HT). Oropharynx was the primary tumor location. Normalization of the three step SIB (77 Gy, 70 Gy, 56 Gy) was D95%=77 Gy. Coverage (CVF), healthy tissue conformity index (HTCI), conformation number (CN), and dose homogeneity (HI) were compared for PTVs and conformation index (COIN) for parotids. Results: All RT techniques achieved good coverage. For SIB77Gy, CVF was best for IMRT and VMAT, HT achieved highest CN followed by VMAT and IMRT. HT reached good HTCI value, and HI compared to both other techniques. For SIB70Gy, CVF was best by IMRT. HTCI favored HT, consequently CN as well. HI was slightly better for HT. For SIB56Gy, CVF resulted comparably. Conformity favors VMAT as seen by HTCI and CN. Dmean of ipsilateral and contralateral parotids favor HT. Conclusion: Different TPS for dose escalation reliably achieved high plan quality. Despite the very good results of HT planning for coverage, conformity, and homogeneity, the TPS also achieved acceptable results for IMRT and VMAT.

DOI: <https://doi.org/10.1186/s13014-020-01693-2>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-194429>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:

Pigorsch, Steffi U; Kampf, Severin; Oechsner, Markus; Mayinger, Michael C; Mozes, Petra; Devecka, Michal; Kessel, Kerstin K; Combs, Stephanie E; Wilkens, Jan J (2020). Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study. *Radiation Oncology*, 15(253):1-10.


DOI: <https://doi.org/10.1186/s13014-020-01693-2>

RESEARCH

Open Access



# Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study

Steffi U. Pigorsch<sup>1\*</sup> , Severin Kampfer<sup>1</sup>, Markus Oechsner<sup>1</sup>, Michael C. Mayinger<sup>3</sup>, Petra Mozes<sup>1</sup>, Michal Devecká<sup>1</sup>, Kerstin K. Kessel<sup>1</sup>, Stephanie E. Combs<sup>1,2</sup> and Jan J. Wilkens<sup>1</sup>

## Abstract

**Background:** The ESCALOX trial was designed as a multicenter, randomized prospective dose escalation study for head and neck cancer. Therefore, feasibility of treatment planning via different treatment planning systems (TPS) and radiotherapy (RT) techniques is essential. We hypothesized the comparability of dose distributions for simultaneous integrated boost (SIB) volumes respecting the constraints by different TPS and RT techniques.

**Methods:** CT data sets of the first six patients (all male, mean age: 61.3 years) of the pre-study (up to 77 Gy) were used for comparison of IMRT, VMAT, and helical tomotherapy (HT). Oropharynx was the primary tumor location. Normalization of the three step SIB (77 Gy, 70 Gy, 56 Gy) was  $D_{95\%} = 77$  Gy. Coverage (CVF), healthy tissue conformity index (HTCI), conformation number (CN), and dose homogeneity (HI) were compared for PTVs and conformation index (COIN) for parotids.

**Results:** All RT techniques achieved good coverage. For SIB77Gy, CVF was best for IMRT and VMAT, HT achieved highest CN followed by VMAT and IMRT. HT reached good HTCI value, and HI compared to both other techniques. For SIB70Gy, CVF was best by IMRT. HTCI favored HT, consequently CN as well. HI was slightly better for HT. For SIB56Gy, CVF resulted comparably. Conformity favors VMAT as seen by HTCI and CN. Dmean of ipsilateral and contralateral parotids favor HT.

**Conclusion:** Different TPS for dose escalation reliably achieved high plan quality. Despite the very good results of HT planning for coverage, conformity, and homogeneity, the TPS also achieved acceptable results for IMRT and VMAT.

*Trial registration* ClinicalTrials.gov Identifier: NCT 01212354, EudraCT-No.: 2010-021139-15. ARO: ARO 14-01

**Keywords:** Dose escalation, Head and neck cancer, Combined chemoradiation therapy, RT planning comparison, IMRT, VMAT, Helical tomotherapy, SIB

## Background

Head and neck cancer patients are treated by intensity modulated radiotherapy (IMRT) as standard of care in radiation oncology. Early in the era of IMRT application,

the concept of the simultaneous integrated boost (SIB) was evaluated [1]. This boost technique creates a selective heterogeneous dose distribution in one target divided into subvolumes with the aim of better conformity [2]. Many results of planning comparisons using different treatment planning systems (TPS) and radiotherapy (RT) treatment concepts have been published for both head and neck as well as other cancer. Many of these used real patient data sets for comparison of treatment modalities at the same institution [3–9]. IMRT, volumetric

\*Correspondence: steffi.pigorsch@tum.de

<sup>1</sup> Department of Radiation Oncology, Technical University of Munich (TUM), School of Medicine, Klinikum Rechts Der Isar, Ismaninger Straße 22, 81675 Munich, Germany

Full list of author information is available at the end of the article



© The Author(s) 2020. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

modulated arc therapy (VMAT), and helical tomotherapy (HT) are routinely used to treat patients with head and neck cancer.

In multicenter prospective trials with IMRT, quality assurance (QA) of RT planning is mandatory [10, 11]. QA for RT of head and neck cancer does not only include the quality of RT plans, but begins earlier in the treatment process. The delineation of the target and organ at risk (OAR) requires standardization and quality control. Especially with the implementation of RT plans with steep dose gradients, the correct target volume delineation is of outstanding importance. Otherwise the clinical outcome of head and neck cancer patients is compromised [11]. Feasibility of the RT-strategy is the first step of RT-trial design. The second step is the proof of dose specification with different TPS, followed by a dummy run of all participating trial centers including a dummy run for target volume and OAR contouring.

The ESCALOX trial was planned as a multicenter trial for dose escalation in head and neck cancer to the gross tumor volume (GTV) defined by CT and MRI imaging in 2010. FMISO-PET was part of a translational research project and not implemented in target volume definition. Data sets of the first six patients of the pre-study as determined by the German Federal Office of Radiation Protection (Bundesamt für Strahlenschutz—BfS) (BfS-registration number Z5-22463/2-2011-011) were used for planning comparison with different TPS. The aim of this planning study was to compare the non-uniform dose prescription and calculated planning target volume (PTV) doses of the different SIB volumes as well as the calculated doses to the OARs between two TPS: Eclipse version 13.0 (Varian Medical Systems, Palo Alto, CA, USA) for VMAT (RapidArc) and dynamic multi-field IMRT, and TomoTherapy Planning Station version 4.2.3 (Accuray, Sunnyvale, CA, USA).

The hypothesis of this investigation was the generation of comparable RT plans via different TPS and RT techniques respecting the dose prescription to the SIB volumes as a primary objective. The secondary planning goal was the concurrent minimization of dose to the organs at risk (OAR) while having an escalated dose of up to 77 Gy in the SIB.

## Methods

### Patient characteristics and RT concept

Patients were treated between 1/2016 and 2/2017 after inclusion in the pre-study of the ESCALOX trial at the Department of Radiation Oncology of the Technical University of Munich. All included patients were male with a smoking history of more than 10 packyears. The mean age was 61.3 years [53–70 years]. In all cases, primary tumor location was the oropharynx, for details, see

Table 1. TNM classification was done according to the 7th edition of UICC, 2010. The mean GTV of primary tumor was 62.6 cm<sup>3</sup> [IQR 22.4–116.4 cm<sup>3</sup>]. Concomitant platin-based chemotherapy was standard of care in all patients. All patients were treated with 35 fractions with 5 fractions per week. Because of the three step SIB concept, each target volume was deemed as SIB: SIB77Gy: 2.2 Gy up to 77 Gy; SIB70Gy: 2.0 Gy up to 70 Gy and SIB56Gy: 1.6 Gy up to 56 Gy (for details see [12]).

### Target delineation

Head and shoulder mask systems were customized before treatment planning CT for all patients (slice thickness 3 mm, intravenous contrast enhancement in all cases). CT extension comprised base of skull to mid-mediastinum. The CT images were reconstructed with 512 × 512 pixel matrices.

Before treatment planning, every patient was also staged by means of a head and neck MRI. These MRI scans were co-registered to the planning CT. Based on the panendoscopy report and the imaging entirety, the GTV, clinical target volume (CTV), and SIB (PTV) were delineated and crosschecked by two radiooncologists (MD, SP). Bilateral neck lymph drainage was PTV in all cases. Every isotropic margin generation by the TPS was re-contoured manually with respect to anatomic structures (bones, ligaments, cartilage, muscle) usually not tumor-invaded as recommended by trial protocol. The RT plans were evaluated quantitatively and qualitatively (isodose curves and color wash) by two physicians.

### Treatment planning—VMAT, IMRT, HT

All plans were calculated, optimized, and approved by experienced medical physicists on the particular system (Eclipse for VMAT and IMRT, and TomoTherapy Planning Station for HT). Normalization was done to 95% of the volume with the highest prescribed dose (SIB77). In the tomotherapy planning workflow, normalization is done during the optimization process. Hence, there can be small discrepancies between the “normalization dose” and the dose after final dose calculation (after which the dose will not be normalized again). The first optimization goal was to bring 95% of the PTV to the specific prescribed doses (Table 2). In addition, 50% of the PTV volumes (SIB77Gy, SIB70Gy, SIB56Gy) were to receive no more than 79.3 Gy, 72.1 Gy, and 57.7 Gy, respectively. The second planning objective was to spare the following OARs according to their constraints or to the ALARA principle: spinal cord (spinal cord + 5 mm) (mandatory), brachial plexus (mandatory), brainstem (mandatory), optical nerve (mandatory), mandible, glottis, and parotid glands.

**Table 1 Patient characteristics**

Characteristics	GTV = SIB77Gy (cm <sup>3</sup> )
Patient 1, male Age at diagnosis: 67 years Diagnosis: OPC (midline of base of tongue) TNM: cT3 cN2b cM0 G3 Histology: SCC, p16+ Treatment: CCRT once Cisplatin 40 mg/m <sup>2</sup> /day, change to 5 × Carboplatin AUC 2 (only one kidney after accident)	86.8
Patient 2, male Age at diagnosis: 70 years Diagnosis: OPC (base of tongue right) TNM: cT2 cN2c cM0 G3 Histology: SCC, p16— Treatment: CCRT with 4 × Cisplatin 40 mg/m <sup>2</sup> /day	77.33
Patient 3, male Age at diagnosis: 53 years Diagnosis: OPC (left soft palate, base of tongue, tongue left side, floor of mouth, exceeding midline) TNM: cT4a cN2c cM0 G3 Histology: SCC, p16— Treatment: CCRT with 6 × Cisplatin 40 mg/m <sup>2</sup> /day	116.4
Patient 4, male Age at diagnosis: 54 years Diagnosis: OPC (left tonsil, submandibular gland, dorsal third of tongue, fossa pterygopalatina) TNM: cT4a cN2c cM0 G3 Histology: SCC, p16— Treatment: CCRT with 6 × Cisplatin 40 mg/m <sup>2</sup> /day	24.6
Patient 5, male Age at diagnosis: 56 years Diagnosis: OPC (left tonsil and fossa) TNM: cT2 cN2b cM0 G2 Histology: SCC, p16— Treatment: CCRT with 6 × Cisplatin 40 mg/m <sup>2</sup> /day	48.3
Patient 6, male Age at diagnosis: 68 years Diagnosis: OPC (right tonsil and soft palate) TNM: cT4a cN2b cM0 G3 Histology: SCC, p16— Treatment: CCRT with 3 × Cisplatin 40 mg/m <sup>2</sup> /day	22.4

**Table 2 ESCALOX—trial dose prescription for SIB-Volumes volumes**

PTV (SIB)	Planning goal D <sub>95%</sub> (Gy)	Planning goal D <sub>50%</sub> (Gy)
SIB77Gy	77	≤ 79.3
SIB70Gy	70	≤ 72.1
SIB56Gy	56	≤ 57.7

For OARs labeled as “mandatory”, the given dose was a hard constraint. In some cases, when it was not possible to fulfill both criteria (PTV dose and mandatory OAR dose—see Table 3), a lower dose in the PTV was accepted (detailed delineation and planning are described in [12]). All planning modalities

**Table 3 Dose constraints for OAR defined by the ESCALOX trial protocol**

OAR	D <sub>95%</sub>	Planning goals as accepted dose [EQD2]
Spinal cord (PRV: spinal cord + 5 mm)	Mandatory	D <sub>max</sub> < 50 Gy <sub>2</sub> or No more than 1 cm <sup>3</sup> > 45 Gy <sub>2</sub>
Brachial plexus	Mandatory	60 Gy <sub>2</sub>
Brainstem	Mandatory	D <sub>max</sub> < 54 Gy <sub>2</sub> or No more than 1 cm <sup>3</sup> > 54 Gy <sub>2</sub>
Optical nerve	Mandatory	D <sub>max</sub> < 54 Gy <sub>2</sub>
Mandible	Recommended	D <sub>max</sub> < 70 Gy <sub>2</sub> or No more than 1 cm <sup>3</sup> > 70 Gy <sub>2</sub>
Glottis (outside PTV)	Recommended	2/3 < 50 Gy <sub>2</sub> D <sub>mean</sub> < 45 Gy <sub>2</sub>
Gl. parotis	Recommended	D <sub>mean</sub> < 26 Gy <sub>2</sub> D <sub>50</sub> < 30 Gy <sub>2</sub> 20 cm <sup>3</sup> of both < 20 Gy <sub>2</sub>

used identical dose criteria for the SIBs and OARs as described in the trial protocol.

### VMAT and IMRT

Treatment planning for the VMAT and dynamic IMRT plans was performed with the Eclipse 13.0 TPS. For dose calculation, the Anisotropic Analytical Algorithm (AAA, version 10.028) was used with a dose grid size of  $2.5 \times 2.5 \times 3.0 \text{ mm}^3$ . VMAT and IMRT planning was performed for treatment using a Varian Clinac Trilogy linear accelerator equipped with a 120 HD MLC. VMAT plans consisted of three arcs with  $358^\circ$  rotation each. The sliding window IMRT plans were optimized using a beam set-up of nine coplanar static beam directions with evenly distributed angular distances.

All plans were normalized to a dose of 77 Gy, covering 95% of the SIB77Gy volume as described in the trial protocol [12]. There were no limits for treatment planning time. Re-optimization for treatment planning was allowed and recommended to push the TPS to the limits.

### Helical tomotherapy

Treatment planning was done with the TomoTherapy Planning Station (Accuray), version 4.2.3. The tomotherapy plans were all helical IMRT plans with field widths of 1 cm and calculation grid size set to fine.

### Dose-volume histogram (DVH) analysis and statistics

All DVH analyses were done using the Eclipse TPS (HT plans were imported). DVH data was extracted to a TXT-file and then read out by R-Software (R version 3.4.1 (2017-06-30)—The R Foundation for Statistical Computing) and spreadsheets. Statistical analysis was calculated by IBM SPSS version 25. The DVH data of each patient was compared for every planning approach (IMRT, VMAT or HT) and between all patients by calculating the mean data for every parameter.

A comparison of the mean DVH data of all techniques was made by using Student's two-sided paired t-test or Wilcoxon test, depending on the distribution of the values (IMRT vs. HT; IMRT vs. VMAT and HT vs. VMAT). Statistical significance was supposed for  $p \leq 0.05$ .

### Parameters for DVH analysis

To compare different RT-plans (VMAT, IMRT and HT), the following DVH-SIB (PTV) parameters were rated: SIB77Gy— $D_{\text{mean}}$ ,  $D_{100\%}$ ,  $D_{98\%}$  ( $D_{\text{min}}$ ),  $D_{25\%}$ ,  $D_{5\%}$  and  $D_{2\%}$  ( $D_{\text{max}}$ ). We defined the SIB70Gy-volume as a shell without the inside-located SIB77Gy-volume. For the SIB56Gy-volume, the same procedure was done to create the shell without SIB70Gy- and SIB77Gy-volumes. For each shell (SIB56Gy and SIB70Gy),  $D_{95\%}$  and  $D_{5\%}$  are reported (Table 4) (for raw data see Additional file 1). For

assessment of plan quality, the coverage factor (CVF), healthy tissue conformity index (HTCI), conformation number (CN) and the homogeneity index (HI) were calculated and compared to each other [3, 13]. These parameters were used to judge the quality of the different planning target volumes (i.e. SIB).

The formulae to calculate all these parameters are given with:

$$1 \text{ CVF—coverage factor [13]} \text{ CVF} = \frac{\text{TVRI}}{\text{TV}}$$

TVRI—irradiated target volume encompassed by reference dose 95%-isodose; TV—target volume.

$$2 \text{ HTCI—healthy tissue conformity index [14]} \text{ HTCI} = \frac{\text{TVRI}}{\text{VRI}}$$

VRI—irradiated volume encompassed by reference 95%-isodose.

$$3 \text{ CN—conformation number [15]} \text{ CN} = \text{CVF} \times \text{HTCI}$$

$$4 \text{ HI—homogeneity index [13]} \text{ HI} = \frac{D_{5\%}}{D_{95\%}}$$

Parameters for OAR for head and neck cancer were reported from DVH and also compared depending on the RT technique (parallel OAR: parotid gland  $D_{\text{mean}}$  [16–18]; larynx  $D_{\text{mean}}$  [19], serial OAR: spinal cord + 5 mm  $D_{\text{max}}$ ; brainstem  $D_{\text{max}}$ , plexus brachialis  $D_{2\%}$ , mandibula  $D_{\text{mean}}$  and  $D_{2\%}$ ). In order to properly assess the OAR doses of the parotid gland, it is important to note that three patients had left-sided and two patients right-sided cancer of the oropharynx. In one case, the tumor was located near the midline with growth to the right. In this way, we used “ipsilateral” parotid gland as the site of primary tumor location and contralateral for the primary tumor free zone. In order to compare the parotid glands (ipsi- or contralateral to the primary tumor), the conformity index was used.

$$5 \text{ COIN—conformity index according to Baltas et al. [20]}$$

$$\text{COIN} = \text{CN} \times \left(1 - \frac{V_{\text{OARref}}}{V_{\text{OAR}}}\right).$$

$V_{\text{OARref}}$  OAR volume receiving reference dose;  $V_{\text{OAR}}$  total volume of OAR.

## Results

All RT plans achieved good to excellent coverage (CVF) for the SIB-volumes. SIB77Gy for IMRT and VMAT had a CVF value of 1.0 and HT achieved a CVF value of  $0.997 \pm 0.007$ . HT yielded best HTCI (HT  $0.372 \pm 0.034$  vs. VMAT  $0.254 \pm 0.103$  vs. IMRT  $0.273 \pm 0.123$ ) and CN (HT  $0.371 \pm 0.033$  vs. VMAT  $0.254 \pm 0.103$  vs. IMRT  $0.273 \pm 0.123$ ), see Table 4.

As for coverage and conformity, HT achieved the best result for dose homogeneity (HI: HT  $1.032 \pm 0.013$  vs. VMAT  $1.054 \pm 0.003$  vs. IMRT  $1.054 \pm 0.006$ ).

**Table 4 Treatment planning results: Dose-volume histogram parameters and coverage, conformity and homogeneity indices for VMAT, IMRT, and HT (mean  $\pm$  SD); ipsilateral corresponds to the tumor site, contralateral to the opposite side of tumor location**

Volume	Para-meter	Unit	VMAT	IMRT	HT	p-value		
						IMRT vs. HT	IMRT vs. VMAT	HT vs. VMAT
SIB77Gy	Volume	cm <sup>3</sup> (range)	54.2 $\pm$ 35.5 Median 37.7					
	D <sub>mean</sub>	Gy	79.1 $\pm$ 0.2	79.2 $\pm$ 0.2	78.5 $\pm$ 0.7	0.048	0.3	0.018
	D <sub>100%</sub>	Gy	72.9 $\pm$ 1.0	72.7 $\pm$ 0.7	73.6 $\pm$ 1.7	0.3	0.3	0.5
	D <sub>98%</sub>	Gy	76.3 $\pm$ 0.2	76.3 $\pm$ 0.2	76.2 $\pm$ 1.3	0.9	0.5	0.9
	D <sub>95%</sub>	Gy	77.0 $\pm$ 0	77.0 $\pm$ 0	77.2 $\pm$ 0.1	0.6	0.1	0.6
	D <sub>2%</sub>	Gy	81.6 $\pm$ 0.2	81.5 $\pm$ 0.5	79.8 $\pm$ 1.0	0.015	0.9	0.013
	D <sub>5%</sub>	Gy	81.2 $\pm$ 0.2	81.2 $\pm$ 0.5	79.6 $\pm$ 1.0	0.026	1.0	0.017
Coverage	CVF		1 $\pm$ 0.00	1 $\pm$ 0.00	0.997 $\pm$ 0.007			
Conformity	HTCI		0.25 $\pm$ 0.10	0.27 $\pm$ 0.11	0.37 $\pm$ 0.03			
	CN		0.25 $\pm$ 0.10	0.27 $\pm$ 0.11	0.37 $\pm$ 0.03			
Homogeneity	HI		1.054 $\pm$ 0.003	1.054 $\pm$ 0.006	1.032 $\pm$ 0.012			
SIB70Gy (excluding SIB77Gy)	Volume	cm <sup>3</sup>	257.4 $\pm$ 112.7 Median 220.7					
	D <sub>95%</sub>	Gy	69.5 $\pm$ 0.2	69.8 $\pm$ 0.3	69.1 $\pm$ 0.8	0.2	0.2	0.4
	D <sub>5%</sub>	Gy	77.8 $\pm$ 0.2	76.9 $\pm$ 0.6	76.7 $\pm$ 0.4	0.1	0.6	0.044
Coverage	CVF		0.995 $\pm$ 0.002	0.997 $\pm$ 0.002	0.995 $\pm$ 0.005			
Conformity	HTCI		0.759 $\pm$ 0.026	0.773 $\pm$ 0.032	0.827 $\pm$ 0.031			
	CN		0.754 $\pm$ 0.024	0.769 $\pm$ 0.032	0.823 $\pm$ 0.032			
Homogeneity	HI		1.145 $\pm$ 0.01	1.142 $\pm$ 0.008	1.141 $\pm$ 0.015			
SIB56Gy (excluding SIB70Gy)	Volume	cm <sup>3</sup> (range)	691.9 $\pm$ 181.2 Median 653.5					
	D <sub>95%</sub>	Gy	55.4 $\pm$ 0.2	55.3 $\pm$ 0.4	55.4 $\pm$ 0.5	1.0	0.5	0.4
	D <sub>5%</sub>	Gy	69.3 $\pm$ 0.3	68.9 $\pm$ 0.8	67.5 $\pm$ 0.8	0.5	0.1	0.015
Coverage	CVF		0.986 $\pm$ 0.004	0.985 $\pm$ 0.004	0.983 $\pm$ 0.005			
Conformity	HTCI		0.747 $\pm$ 0.024	0.731 $\pm$ 0.027	0.728 $\pm$ 0.031			
	CN		0.739 $\pm$ 0.023	0.723 $\pm$ 0.029	0.719 $\pm$ 0.031			
Homogeneity	HI		1.391 $\pm$ 0.018	1.384 $\pm$ 0.018	1.381 $\pm$ 0.020			
Organs at risk								
Parotid Glands both	COIN		0.606 $\pm$ 0.040	0.593 $\pm$ 0.032	0.603 $\pm$ 0.065			
ipsilateral	D <sub>mean</sub>	Gy	32.8 $\pm$ 4.8	33.1 $\pm$ 4.4	31.1 $\pm$ 4.0	0.046	0.345	0.043
	Volume	cm <sup>3</sup>	30.4 $\pm$ 6.0					
	COIN		0.555 $\pm$ 0.047	0.548 $\pm$ 0.040	0.546 $\pm$ 0.073	0.917	0.345	0.753
Contralateral	D <sub>mean</sub>	Gy	26.3 $\pm$ 3.9	26.2 $\pm$ 3.6	22.6 $\pm$ 5.5	0.116	0.173	0.043
	Volume	cm <sup>3</sup>	26.9 $\pm$ 5.5					
	COIN		0.665 $\pm$ 0.043	0.647 $\pm$ 0.040	0.664 $\pm$ 0.063	0.345	0.028	0.917
Spinal cord + 5 mm	D <sub>max</sub>	Gy	50.5 $\pm$ 1.4	51.9 $\pm$ 1.7	45.7 $\pm$ 7.4			
Brainstem	D <sub>max</sub>	Gy	27.4 $\pm$ 7.45	29.07 $\pm$ 1.9	25.94 $\pm$ 5.9	0.1	0.1	0.037
Larynx	D <sub>mean</sub>	Gy	45.2 $\pm$ 6.1	44.7 $\pm$ 5.8	43.3 $\pm$ 8.7			
Plexus brachialis Ipsilateral	D <sub>2%</sub>	Gy	58.5 $\pm$ 0.4	58.0 $\pm$ 0.9	57.6 $\pm$ 1.6	0.345	0.345	0.138
	COIN		0.306 $\pm$ 0.159	0.398 $\pm$ 0.433	0.505 $\pm$ 0.172	0.116	0.075	0.028
Plexus brachialis contralateral	D <sub>2%</sub>	Gy	58.5 $\pm$ 0.3	58.1 $\pm$ 0.3	57.9 $\pm$ 1.4	0.463	0.046	0.138
	COIN		0.279 $\pm$ 0.141	0.355 $\pm$ 0.155	0.535 $\pm$ 0.178	0.028	0.028	0.028
Mandibula	D <sub>mean</sub>	Gy	46.0 $\pm$ 7.2	48.7 $\pm$ 6.1	44.2 $\pm$ 7.7	0.014	0.025	0.1
	D <sub>2%</sub>	Gy	70.7 $\pm$ 3.3	71.2 $\pm$ 2.6	71.9 $\pm$ 2.5	0.2	0.6	0.2



SIB70Gy had best coverage with the IMRT plan (CVF  $0.997 \pm 0.002$  vs.  $0.995 \pm 0.002$  for VMAT and  $0.995 \pm 0.005$  for HT). HT achieved a very good HTCI ( $0.827 \pm 0.034$ ) vs.  $0.759 \pm 0.01$  for VMAT and  $0.773 \pm 0.035$  for IMRT. As a consequence of the high HTCI, the tomotherapy plan reached the highest conformation number (CN)  $0.823 \pm 0.035$  compared to IMRT (CN  $0.769 \pm 0.035$ ) and VMAT (CN  $0.754 \pm 0.024$ ) for SIB70Gy. Homogeneity calculation favors HT (HI: HT  $1.141 \pm 0.016$  vs. IMRT  $1.142 \pm 0.009$  vs. VMAT  $1.145 \pm 0.01$ ).

For SIB56Gy, the coverage parameter CVF was comparable in all three RT technique plans between  $0.983 \pm 0.006$  and  $0.986 \pm 0.004$ . In contrast to the SIB77Gy and SIB70Gy, the SIB56Gy conformity analysis using HTCI and CN favors VMAT (HTCI:  $0.747 \pm 0.024$  and CN  $0.739 \pm 0.023$ ). IMRT (HTCI:  $0.731 \pm 0.029$ ; CN:  $0.723 \pm 0.031$ ) and HT (HTCI:  $0.728 \pm 0.034$ ; CN:  $0.719 \pm 0.033$ ) achieved lower results. Plan examples are given in Fig. 1.

The comparison check done by Student's two-sided paired t-test (IMRT vs. HT, IMRT vs. VMAT, and HT vs. VMAT) reveals a significant difference concerning  $D_{\text{mean}}$ ,  $D_{2\%}$  and  $D_{5\%}$  for SIB77Gy between all RT techniques, favoring HT.  $D_{5\%}$  differed significantly for SIB70Gy and SIB56Gy with the best results by HT.

$D_{\text{mean}}$  to the ipsilateral parotid gland varied between  $31.1 \pm 4.0$  Gy (HT),  $33.1 \pm 4.4$  Gy (IMRT) and  $32.8 \pm 4.8$  Gy (VMAT) and contralateral between  $22.6 \pm 5.5$  Gy (HT),  $26.2 \pm 3.6$  Gy (IMRT) and  $26.3 \pm 3.9$  Gy (VMAT). HT showed minimally better results for ipsilateral parotid glands vs. VMAT and IMRT. IMRT and VMAT achieved comparable results. For the contralateral parotid gland, there was only an advantage of HT compared to VMAT ( $p = 0.043$ ).

The  $D_{\text{max}}$  for the spinal cord plus 5 mm was comparably safe for all kinds of radiotherapy. Interestingly, HT reached the lowest  $D_{\text{max}}$   $45.7 \pm 8.2$  Gy, but the highest standard deviation.

For comparison of the plexus brachialis, this OAR was also discriminated between ipsilateral and contralateral localization. Concerning  $D_{2\%}$  only for the contralateral plexus, a small significant difference was reached for IMRT vs. VMAT, favoring IMRT.

The  $D_{\text{mean}}$  of the mandible was  $44.2 \pm 8.5$  Gy for HT,  $46.0 \pm 7.9$  Gy for VMAT, and  $48.7 \pm 6.7$  Gy for IMRT. VMAT and HT were significantly better than IMRT (VMAT vs. IMRT  $p = 0.025$ ).  $D_{\text{mean}}$  of the mandible could be lowered by HT compared to VMAT ( $p = 0.014$ ).  $D_{2\%}$  for mandible was comparably high for all used techniques (VMAT:  $70.7 \pm 3.6$  Gy; IMRT:  $71.2 \pm 2.8$  Gy and HT:  $71.9 \pm 2.7$  Gy).


## Discussion

The aim of this planning study was to investigate the planning options for the first six patients enrolled in the pre-study of the ESCALOX trial. Thus, IMRT, VMAT, and HT planning algorithms and the corresponding RT plans were compared and checked for the constraints as determined by the trial protocol [12]. Different plan quality parameters were calculated from DVH for all planning target volumes (SIB77Gy, SIB70Gy, and SIB56Gy) in order to compare all RT techniques. Dose coverage, dose conformity, and homogeneity were analyzed. For SIB77Gy, SIB70Gy, and SIB56Gy, the coverage of all RT modalities was comparable. HT gained best results for SIB77Gy concerning conformity (HTCI and CN) and homogeneity defined by the HI. Concerning coverage (CVF) of HT for SIB77Gy, there was a small gap between HT and VMAT and IMRT, which seems clinically irrelevant.

The SIB70Gy volume encompassed the shell between the margin of SIB77Gy and SIB70Gy. Best coverage for SIB70Gy was achieved by IMRT. Conformity and homogeneity favored HT. The analysis of SIB56Gy—the volume for elective nodal irradiation—revealed a comparable coverage for all RT modalities. Best conformity was reached by VMAT, superior homogeneity by HT. Thus, HT is favored for conformity defined by HTCI and CN for the SIB77Gy and SIB70Gy. Best performance for homogeneity (HI) in all SIBs was achieved only by HT, followed by IMRT. Important DVH parameters describing the steepness of the dose gradient as  $D_2$  or  $D_5$  as well as  $D_{\text{mean}}$  showed better results for HT, but no differences between IMRT and VMAT. Despite the shown advantage of HT, all RT modalities fulfilled the dose specification of the trial protocol: 50% of the PTV volumes (SIB77, SIB70, SIB56) should receive no more than 79.3 Gy, 72.1 Gy, and 57.7 Gy, respectively.

Differding et al. compared in a RT planning study the potential of VMAT and HT in part 1 for best target coverage and in part 2 for maximal OAR sparing [5, 21]. This was an FDG-PET based delineation for dose painting planning study on datasets of five patients with oropharyngeal cancer. HT and VMAT achieved comparable results for target coverage (PTV 70 Gy (SIB) and PTV 56 Gy applied in 35 fractions) and OAR sparing. Slight differences were seen for conformity of PTV 56 Gy favoring HT. The authors concluded that HT and VMAT were able to deliver similar dose distributions for FDG-PET-based dose escalation for the concept of dose painting by numbers. The good results for VMAT were at the cost of four arcs. The planning physicists extended the limits of the TPS by re-optimization of the RT plans after comparing their results to the other TPS results. For our planning scenario, both physicists did the same.





**Fig. 1** Examples of isodose distribution and DVH of VMAT, IMRT and HT for patient 2. SIB colours: SIB 77 Gy—yellow, SIB 70 Gy—orange, SIB 56 Gy—red. OAR colours: brainstem—magenta, left parotid gland—green, right parotid gland—blue, spinal cord—brown, left plexus brachialis—light green, right plexus brachialis—light blue

In order to yield comparable results for target coverage and to minimize the OAR dose, VMAT applies the dose by using three arcs. Despite one additional arc compared to a routine head and neck RT plan, the beam on time is lower than the amount of time of application of an HT plan. This indicates that the probability of intra-fraction motion is smaller by VMAT than with HT.

Thorwarth et al. compared 9-field step and shoot IMRT with HT for inhomogeneous dose distribution by dose painting by numbers for dose escalation to hypoxic subvolumes. HT achieved a higher degree of conformity. Therefore, in this planning competition, the authors summarized both implemented techniques (IMRT and HT) as suitable for dose escalation [6]. Only small differences for target coverage were seen by Stromberger et al. for planning comparison of a SIB concept in bilateral and unilateral neck irradiation for intensity modulated proton therapy (IMPT), HT, and VMAT [3].

Concerning OARs, the comparison of DVH parameters for parotid gland, brainstem, and mandible saw HT ahead in our investigation. Despite the favored position of HT in many parameters, IMRT and VMAT ensured safe coverage of target volumes and adherence to the OAR constraints per trial protocol. The small differences seen in the head-to-head comparison will probably have no impact on clinical outcome. Other groups investigating different RT techniques and fractionation concepts for head and neck cancer hypothesized no clinical impact of small dosimetric differences [5, 7] as well. Comparing  $D_{\text{mean}}$  to the ipsilateral parotid gland, we achieved the lowest dose by HT (31.1 Gy). There was a difference of 2 Gy compared to IMRT (33.1 Gy). HT reached also best contralateral  $D_{\text{mean}}$  (22.6 Gy) to the parotid gland (VMAT and IMRT > 26 Gy). Jacob et al. investigated the influence of leaf and jaw parameter on plan quality for head and neck RT in nine patients by IMRT, VMAT, and HT. They concluded that all plans fulfilled OAR constraints, but HT lowered the dose to the parotid glands by best dose homogeneity. Changes of leaf thickness and jaw width had no additional benefit for OAR sparing [22]. Inconsistent results favoring one technique over another for dose reduction to salivary glands are reported [9, 23–27]. The groups of Wiezorek [27] and Holt [28] examined head and neck RT plans created by diverse IMRT techniques and various machine parameters between different institutions, the conclusion was the same as in many single center experiences: good target coverage and acceptable OAR sparing for all techniques with slight preference. At one point, HT was superior, on occasion VMAT or IMRT. Both multicenter planning comparison trials delineated the PTV (respective SIB volumes) and OARs in the core unit. Thus, the uncertainty in target volume delineation was excluded and the results clearly

concentrate on the physical aspect of RT planning and treatment delivery. The aim of this study consisted in proof of principle for using different TPS for planning of real patients in preparation of a multicenter study. For the purpose of initiating a multicenter IMRT-trial, a dummy run for all participating centers with a central QA core unit would be necessary. Early on, this was recommended by Wallner et al. in 1989 [29] and renewed by McDowell in 2019 [10]. In order to reduce unnecessary dose deposition to OARs and surrounding healthy tissue, the trial protocol recommended triple re-planning [12] based on results of the work of Duma et al. [30] and others e.g. [31]. The onboard imaging units of linear accelerators increase the accuracy of patient positioning (daily CB-CT, MV-CT) and allow for adaptive planning. Consequently, the target volumes and OARs can be observed and adapted if necessary.

This analysis was done with the primary image set for initial RT planning. The re-planning scenarios as performed for each patient during the pre-study are not shown.

MRI for GTV definition is important for safety of target and OAR delineation due to better spatial resolution. Over the last years, many results were confirmed for implementation of molecular imaging and widened sequences of MRI, e.g. diffusion-weighted MRI for GTV definition [32] and also better definition of OAR, for instance, swallowing structures [33]. In a dummy run, Felice et al. demonstrated the smaller GTV definition and lower inter-observer variability for MRI-based contouring compared to CT-based target volume definition [34]. Implementation of molecular imaging is a widely investigated field, not only in RT planning of head and neck cancer [35]. Some trials investigating dose escalation integrate the PET signal by employing different tracers and voxel-based RT-planning [5, 6, 36–39]. Hence, the dose escalation strategy based on PET data to overcome troubleshooters like hypoxia or proliferation is not clear [40]. Until now, no large randomized trial on this topic has been published. Despite the advent of implementation of biological imaging into target volume delineation for head and neck cancer treatment aimed at attacking, for instance, hypoxic subvolumes by dose escalation, we resigned at the level of the pre-study of the performance of 18-F-FMISO-PET.

We generated in one center the presented results by calculating 18 different RT plans for a dose escalation study by using the two TPS on datasets of six real patients. The planning group consisted of two radiation oncologists (SP and MD) and two physicists (SK and MO) experienced in the TPS for head and neck cancer planning. Our results are comparable to those of other investigators of single or multicenter planning studies

despite our homogeneous in-house team. The statistical results of small sample sizes always require careful interpretation. A significant difference detection calls for a defined number of dose values or a large difference between the values of the comparators. Possible sources for bias are discussed by van Gestel et al. contributing to different interpretations of planning comparisons by various investigators. One of the drawbacks of our study is the use of only those TPS which were available at our department and the limited number of patients. However, in light of these limitations, it was possible to reach the planning objectives defined by the ESCALOX trial protocol [12].

## Conclusion

The analysis of the quality parameters for RT planning revealed that the tested TPS can produce comparable plan quality for this dose escalation trial. Despite the very good results of HT planning for coverage, conformity, and homogeneity of these plans, also the TPS for calculation of VMAT and IMRT achieved acceptable results for a double simultaneous integrated boost concept for dose escalation in head and neck cancer delivered by IMRT or VMAT. The tested TPS and IMRT-techniques are allowed for the ESCALOX trial.

## Supplementary information

**Supplementary information** accompanies this paper at <https://doi.org/10.1186/s13014-020-01693-2>.

**Additional file 1.** Raw data from DVH for analysis of plan comparison parameter.

## Abbreviations

AAA: Anisotropic Analytical Algorithm; ALARA: As Low as Reasonable Achievable; CB-CT: Cone beam CT; CN: Conformation number; COIN: Conformity index; CT: Computed tomography; CVF: Coverage factor; D: Dose; DVH: Dose Volume Histogram; FDG-PET: Fluorodesoxyglucose positron emission tomography; 18-F-FMISO-PET: 18-Fluoro-Fluoromisonidazol positron emission tomography; GTV: Gross tumor volume; HI: Homogeneity index; HT: Helical tomotherapy; HTCI: Healthy tissue conformity index; IMRT: Intensity Modulated Radiotherapy; MRI: Magnetic Resonance Imaging; MV-CT: Megavoltage CT; OAR: Organ at risk; PTV: Planning target volume; QA: Quality assurance; RT: Radiotherapy; SIB: Simultaneous integrated boost; TPS: Treatment planning system; TV: Target volume; TVRI: Irradiated target volume encompassed by reference dose 95%-isodose; VMAT: Volumetric Modulated Arc Therapy; VRI: Irradiated volume encompassed by reference 95%-isodose.

## Acknowledgements

We would like to thank all the participating patients of this trial. The authors gratefully acknowledge the native speaking support of Dr Sabrina Renfro-Kohl.

## Authors' contributions

PTV-definition by SP and MD. RT plans were evaluated quantitatively and qualitatively (isodose curves and color wash) by two physicians (SP and MD). Treatment plan optimization: SK, MO. Statistical analysis: MM, KK. Manuscript writing: SP, JW and SC discussed the data and manuscript writing. All authors read and approved the final manuscript.

## Funding

Open Access funding enabled and organized by Projekt DEAL. The ESCALOX trial was supported by the Deutsche Forschungsgemeinschaft (DFG); Grant No.: MO-363/4-1.

## Availability of supporting data

The dataset supporting the conclusions of this article is included within the article and its Additional file 1.

## Ethical approval and consent to participate

The final protocol was approved by the ethics committee of the Medical Faculty of the Technical University of Munich (2847/10 Af) and the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte—BfArM; BfArM-registration number 4036421) and the German Federal Office of Radiation Protection (Bundesamt für Strahlenschutz—BfS) (BfS-registration number Z5-22463/2–2011-011). Written informed consent was obtained from each patient in oral and written form before inclusion in the trial. Nature, scope and possible consequences of which has been explained by the responsible physician.

## Consent for publication

All authors agreed to publish the presented results and read the final version of the submitted paper.

## Competing interests

No one of the authors declare conflict of interest for this work.

## Author details

<sup>1</sup> Department of Radiation Oncology, Technical University of Munich (TUM), School of Medicine, Klinikum Rechts Der Isar, Ismaninger Straße 22, 81675 Munich, Germany. <sup>2</sup> Institute of Radiation Medicine (IRM), Helmholtz Zentrum München, Ingolstädter Landstraße 1, Neuherberg, Germany. <sup>3</sup> Department of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, Zurich, Switzerland.

Received: 28 July 2020 Accepted: 21 October 2020

Published online: 02 November 2020

## References

1. Lauve A, Morris M, Schmidt-Ullrich R, Wu Q, Mohan R, Abayomi O, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II—clinical results. *Int J Radiat Oncol Biol Phys*. 2004;60(2):374–87.
2. Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. *Int J Radiat Oncol Biol Phys*. 2000;46(3):619–30.
3. Stromberger C, Włodarczyk W, Marnitz S, Jamil B, Budach V, Raguse JD, et al. Simultaneous integrated boost (SIB): RapidArc and tomotherapy plan comparison for unilateral and bilateral neck irradiation. *Anticancer Res*. 2015;35(5):2991–7.
4. Fakhrian K, Oechsner M, Kampfer S, Schuster T, Molls M, Geinitz H. Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk: planning study in esophageal carcinoma. *Strahlenther Onkol*. 2013;119(4):293–300.
5. Differding S, Sterpin E, Hermand N, Vanstraelen B, Nuyts S, de Patoul N, et al. Radiation dose escalation based on FDG-PET driven dose painting by numbers in oropharyngeal squamous cell carcinoma: a dosimetric comparison between Tomotherapy-HA and RapidArc. *Radiat Oncol*. 2017;12(1):59.
6. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. *Int J Radiat Oncol Biol Phys*. 2007;68(1):291–300.
7. Clemente S, Wu B, Sanguineti G, Fusco V, Ricchetti F, Wong J, et al. Smart-Arc-based volumetric modulated arc therapy for oropharyngeal cancer: a dosimetric comparison with both intensity-modulated radiation therapy and helical tomotherapy. *Int J Radiat Oncol Biol Phys*. 2011;80(4):1248–55.

8. Ekici K, Pepele EK, Yaprak B, Temelli O, Eraslan AF, Kucuk N, et al. Dosimetric comparison of helical tomotherapy, intensity-modulated radiation therapy, volumetric-modulated arc therapy, and 3-dimensional conformal therapy for the treatment of T1N0 glottic cancer. *Med Dosim*. 2016;41(4):329–33.
9. Servagi Vernat S, Ali D, Puyraveau M, Viard R, Lisbona A, Fenoglietto P, et al. Is IMAT the ultimate evolution of conformal radiotherapy? Dosimetric comparison of helical tomotherapy and volumetric modulated arc therapy for oropharyngeal cancer in a planning study. *Physica Med*. 2014;30(3):280–5.
10. McDowell L, Corry J. Radiation therapy quality assurance in head and neck radiotherapy—moving forward. *Oral Oncol*. 2019;88:180–5.
11. Peters LJ, O'Sullivan B, Giral T, Fitzgerald TJ, Trotti A, Bernier J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. *J Clin Oncol*. 2010;28(18):2996–3001.
12. Pigorsch SU, Wilkens JJ, Kampfer S, Kehl V, Hapfelmeier A, Schlager C, et al. Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol. *Radiat Oncol*. 2017;12(1):45.
13. Feuvret L, Noel G, Mazon JJ, Bey P. Conformity index: a review. *Int J Radiat Oncol Biol Phys*. 2006;64(2):333–42.
14. Armstrong J, Raben A, Zelefsky M, Burt M, Leibel S, Burman C, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. *Radiother Oncol*. 1997;44(1):17–22.
15. van't Riet A, Mak AC, Moerland MA, Elders LH, van der Zee W. A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. *Int J Radiat Oncol Biol Phys*. 1997;37(3):731–6.
16. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. *Int J Radiat Oncol Biol Phys*. 2001;50(3):695–704.
17. Eisbruch A, Rhodus N, Rosenthal D, Murphy B, Rasch C, Sonis S, et al. The prevention and treatment of radiotherapy—induced xerostomia. *Semin Radiat Oncol*. 2003;13(3):302–8.
18. Eisbruch A, Ship JA, Dawson LA, Kim HM, Bradford CR, Terrell JE, et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. *World J Surg*. 2003;27(7):832–7.
19. Rancati T, Schwarz M, Allen AM, Feng F, Popovtzer A, Mittal B, et al. Radiation dose-volume effects in the larynx and pharynx. *Int J Radiat Oncol Biol Phys*. 2010;76(3 Suppl):S64–9.
20. Baltas D, Kolotas C, Geramani K, Mould RF, Ioannidis G, Kekchidi M, et al. A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy. *Int J Radiat Oncol Biol Phys*. 1998;40(2):515–24.
21. Differding S, Sterpin E, Janssens G, Hanin FX, Lee JA, Gregoire V. Methodology for adaptive and robust FDG-PET escalated dose painting by numbers in head and neck tumors. *Acta Oncol*. 2016;55(2):217–25.
22. Jacob V, Bayer W, Astner ST, Busch R, Kneschaurek P. A planning comparison of dynamic IMRT for different collimator leaf thicknesses with helical tomotherapy and RapidArc for prostate and head and neck tumors. *Strahlenther Onkol*. 2010;186(9):502–10.
23. Stromberger C, Ghadjar P, Marnitz S, Thieme AH, Jahn U, Raguse JD, et al. Comparative treatment planning study on sequential vs simultaneous integrated boost in head and neck cancer patients: differences in dose distributions and potential implications for clinical practice. *Strahlenther Onkol*. 2016;192(1):17–24.
24. Stromberger C, Cozzi L, Budach V, Fogliata A, Ghadjar P, Wlodarczyk W, et al. Unilateral and bilateral neck SIB for head and neck cancer patients: Intensity-modulated proton therapy, tomotherapy, and RapidArc. *Strahlenther Onkol*. 2016;192(4):232–9.
25. Van Gestel D, van Vliet-Vroegindeweij C, Van den Heuvel F, Crijns W, Coelmont A, De Ost B, et al. RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison. *Radiat Oncol*. 2013;8:37.
26. Van Gestel D, De Kerf G, Wouters K, Crijns W, Vermorken JB, Gregoire V, et al. Fast Helical Tomotherapy in a head and neck cancer planning study: is time priceless? *Radiat Oncol*. 2015;10:261.
27. Wiezorek T, Brachwitz T, Georg D, Blank E, Fotina I, Habl G, et al. Rotational IMRT techniques compared to fixed gantry IMRT and tomotherapy: multi-institutional planning study for head-and-neck cases. *Radiat Oncol*. 2011;6:20.
28. Holt A, Van Gestel D, Arends MP, Korevaar EW, Schuring D, Kunze-Busch MC, et al. Multi-institutional comparison of volumetric modulated arc therapy vs intensity-modulated radiation therapy for head-and-neck cancer: a planning study. *Radiat Oncol*. 2013;8:26.
29. Wallner PE, Lustig RA, Pajak TF, Robinson G, Davis LW, Perez CA, et al. Impact of initial quality control review on study outcome in lung and head/neck cancer studies—review of the Radiation Therapy Oncology Group experience. *Int J Radiat Oncol Biol Phys*. 1989;17(4):893–900.
30. Duma MN, Kampfer S, Schuster T, Winkler C, Geinitz H. Adaptive radiotherapy for soft tissue changes during helical tomotherapy for head and neck cancer. *Strahlenther Onkol*. 2012;188(3):243–7.
31. Castadot P, Geets X, Lee JA, Gregoire V. Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort? *Radiother Oncol*. 2011;101(3):343–50.
32. Gregoire V, Thorwarth D, Lee JA. Molecular imaging-guided radiotherapy for the treatment of head-and-neck squamous cell carcinoma: does it fulfill the promises? *Semin Radiat Oncol*. 2018;28(1):35–45.
33. Alterio D, Ciardo D, Preda L, Argenone A, Caspiani O, Micera R, et al. Contouring of the pharyngeal superior constrictor muscle (PSCM). A cooperative study of the Italian Association of Radiation Oncology (AIRO) Head and Neck Group. *Radiother Oncol*. 2014;112(3):337–42.
34. de Felice F, Musio D, Bulzonetti N, Maghella F, Tombolini V. Target volume delineation based on diffusion-weighted magnetic resonance imaging for locally advanced head and neck cancer. *Anticancer Res*. 2016;36(8):4181–5.
35. Chauhan D, Rawat S, Sharma MK, Ahlawat P, Pal M, Gupta G, et al. Improving the accuracy of target volume delineation by combined use of computed tomography, magnetic resonance imaging and positron emission tomography in head and neck carcinomas. *J Cancer Res Therap*. 2015;11(4):746–51.
36. Welz S, Monnich D, Pfannenberger C, Nikolaou K, Reimold M, La Fougere C, et al. Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. *Radiother Oncol*. 2017;124(3):526–32.
37. Berwouts D, Olteanu LA, Duprez F, Vercauteren T, De Gersem W, De Neve W, et al. Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial. *Radiother Oncol*. 2013;107(3):310–6.
38. Madani I, Duprez F, Boterberg T, Van de Wiele C, Bonte K, Deron P, et al. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. *Radiother Oncol*. 2011;101(3):351–5.
39. Duprez F, De Neve W, De Gersem W, Coghe M, Madani I. Adaptive dose painting by numbers for head-and-neck cancer. *Int J Radiat Oncol Biol Phys*. 2011;80(4):1045–55.
40. Hamming-Vrieze O, Navran A, Al-Mamgani A, Vogel WV. Biological PET-guided adaptive radiotherapy for dose escalation in head and neck cancer: a systematic review. *Q J Nucl Med Mol Imaging*. 2018;62(4):349–68.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.